Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing
In a 14 center study called “DIRECT2,” one of the sites was led by investigators at the
“There are many advantages to quickly diagnosing the specific type of infection a patient has,” said lead author of the DIRECT2 study
The DIRECT2 study finds strong, reliable performance of the
T2Candida Paneldetected 89% of confirmed infections across a large patient population (N=152). T2Candida Paneldetected almost twice as many confirmed infections as blood culture in patients receiving antifungal therapy. This indicates that the T2Candida Panelis a more effective diagnostic tool for patients treated with pre-emptive or empiric antifungal therapy.
- The median time to detection of Candida by diagnostic blood cultures and subsequent species identification was 3.4 days. In comparison, the
T2Candida Panelprovides diagnostic results in an average time of 4.4 hours.
In the DIRECT2 paper, the authors conclude that “T2Candida is an important advance in the diagnosis of candidemia. The panel is the first commercial application of T2MR technology in a diagnostic assay and it ushers in a new era in which rapid molecular testing for invasive candidiasis will serve as an adjunct to microbiologic cultures.”
The second study, called “STAMP” and published in the
The STAMP study evaluated running multiple diagnostic tests for patients with confirmed Candida infections who were receiving antifungal drugs. The study demonstrated that the
The T2Candida Panelwas positive in 23 patient samples, compared to only 7 for blood culture in cases of true infection. The T2Candida Panelidentified every infection that was detected by blood culture and provided actionable results 3 days earlier than blood culture. The T2Candida Paneldetected a Candida infection that blood culture missed in 1 patient during the study.
- Two consecutively negative
T2Candida Panelresults represent a better indicator of clearance of an infection in patients treated with antifungal therapy or where the source of infection was controlled.
- STAMP study data suggest that serial testing of patients with the
T2Candida Panelmay enable more timely management of infections, de-escalation of therapy, better source control and overall reduced costs of care.
“These studies add to the growing evidence that the
About Candida infections
Candida is one of the deadliest sepsis-causing pathogens with a startling mortality rate of approximately 40 percent. It is one of the leading hospital-acquired bloodstream infections in the United States and half of Candida infections are misdiagnosed as being negative by blood culture. The patient and economic impacts of Candida are tremendous: patients average 40 days in the hospital at a cost of $130,000. Studies have shown that every hour of delayed treatment increases the risk of mortality by nearly eight percent. Blood culture-based diagnostic tests, which are the current standard of care, typically require one to six or more days to deliver a result as compared to the
About T2 Biosystems
About the T2Sepsis Solution
Sepsis, one of the deadliest and most expensive conditions in hospitals today, is the focus of the T2Sepsis Solution, a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx® Instrument and T2Candida Panel, and the T2Bacteria® Panel. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. It has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2Bacteria Panel is commercially available in Europe and other countries that accept the CE Mark and is available for research use only in the U.S.